INTERNATIONAL PATENT: MBRACE THERAPEUTICS, INC. FILES APPLICATION FOR "ANTIBODY-DRUG CONJUGATES AGAINST EPH RECEPTOR A5 (EPHA5) FOR TREATMENT OF CARCINOMA"

GENEVA, Oct. 6 -- MBRACE THERAPEUTICS, INC. (4660 La Jolla Village Drive, Suite 895San Diego, California 92122) filed a patent application (PCT/US2025/022153) for "ANTIBODY-DRUG CONJUGATES AGAINST EPH RECEPTOR A5 (EPHA5) FOR TREATMENT OF CARCINOMA" on Mar 28, 2025. With publication no. WO/2025/208100, the details related to the patent application was published on Oct 02, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): STAQUICINI, Fernanda, ALLEY, Steve

Abstract: The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g...